Clinical Trial Update: A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluated sunitinib (Sutent) for recurrent anaplastic astrocytoma and glioblastoma. The results were posted in October 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Anaplastic Astrocytoma, Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2012-10-31